v3.25.0.1
Fair Value Measurements and Marketable Equity Securities - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Aug. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Aug. 30, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration classified as equity, fair value disclosure     $ 775    
Aggregate proceeds from sale of marketable equity securities   $ 23,098 0 $ 0  
Purchase of additional shares of common stock value     3,602    
Marketable equity securities outstanding   $ 107,309 31,807    
Investment In Recursion Pharmaceuticals Class A Common Stock [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Investment in equity securities at fair value sold number of shares   1,725,902      
Weighted average price per share of investment sold   $ 13.38      
Aggregate proceeds from sale of marketable equity securities   $ 23,100      
Fair Value, Inputs, Level 1 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration classified as equity, fair value disclosure     0    
Fair Value, Inputs, Level 2 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration classified as equity, fair value disclosure     0    
Company recognized gain due change fair value of warrant asset   18,300      
Fair Value, Inputs, Level 3 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration classified as equity, fair value disclosure     775    
Company recognized gain (loss) due change fair value of warrant liability   42,400 8,000 4,700  
Warrant [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Warrant issued   100,000      
Company recognized gain net of warrant termination   $ 39,100      
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Class Of Warrant Share Issued   9,218,800     9,218,800
Common stock purchase price $ 18,400        
Purchase of additional shares of common stock 3,500,000        
Purchase of additional shares of common stock value $ 17,700        
Outstanding common stock percentage 20.00%        
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312024 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 1.5      
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312025 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 2.5      
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Prior December312024 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Class Of Warrant Share Issued   4,609,400      
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312024 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Class Of Warrant Excisable At Cash   4,609,400      
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312025 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Class Of Warrant Excisable At Cash   4,609,400      
Contingent Consideration [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration cash payment   $ 1,000      
Contingent upon revenue target     1,500    
Contingent consideration classified as equity, fair value disclosure   $ 800      
Contingent Consideration [Member] | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Company recognized gain due to change in fair Value of contingent consideration     $ 400 $ 3,700  
Contingent Consideration [Member] | Common Stock [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration arrangement of non voting common stock   35,000      
Contingent Consideration [Member] | Common Stock [Member] | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Contingent consideration arrangement of non voting common stock   35,000